PPD downgraded by JP Morgan with a new price target
$PPD
Biotechnology: Commercial Physical & Biological Resarch
Health Care
JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2021 | $47.50 | Neutral | Credit Suisse |
Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the
WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (NASDAQ:PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapi
PPD, Inc. (NASDAQ:PPD) was named one of the "Best Workplaces in Greater China™ 2021" by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. "We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year," said D
Credit Suisse resumed coverage of PPD with a rating of Neutral and set a new price target of $47.50
JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00
Jefferies downgraded PPD from Buy to Hold
15-12B - PPD, Inc. (0001793294) (Filer)
S-8 POS - PPD, Inc. (0001793294) (Filer)
8-K - PPD, Inc. (0001793294) (Filer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
4 - PPD, Inc. (0001793294) (Issuer)
Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the
SC 13G - PPD, Inc. (0001793294) (Subject)
SC 13G - PPD, Inc. (0001793294) (Subject)
SC 13G - PPD, Inc. (0001793294) (Subject)
PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) f